Analysts expect Teva Pharmaceutical Industries Limited (NYSE: TEVA – Get a rating) will report earnings per share (EPS) of $0.55 for the current fiscal quarter, Zacks reports. Five analysts made earnings estimates for Teva Pharmaceutical Industries, with the lowest EPS estimate being $0.50 and the highest estimate $0.61. Teva Pharmaceutical Industries reported earnings of $0.63 per share in the same quarter last year, indicating a negative 12.7% year-over-year growth rate. The company is expected to announce its next quarterly results before the market opens on Monday, January 1.
According to Zacks, analysts expect Teva Pharmaceutical Industries to report annual earnings of $2.53 per share for the current fiscal year, with EPS estimates ranging from $2.45 to $2.60. For the next fiscal year, analysts expect the company to post earnings of $2.66 per share, with EPS estimates ranging from $2.52 to $2.81. Zacks EPS calculations are an average average based on a survey of research companies that cover Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE: TEVA – Get a rating) last released its quarterly earnings data on Wednesday, February 9. The company reported earnings per share (EPS) of $0.74 for the quarter, beating analyst consensus estimates of $0.70 by $0.04. Teva Pharmaceutical Industries had a return on equity of 24.40% and a net margin of 2.63%. The company posted revenue of $4.10 billion in the quarter, versus $4.28 billion expected by analysts. In the same quarter a year earlier, the company posted earnings per share of $0.64.
A number of stock analysts have recently released reports on the stock. Barclays downgraded shares of Teva Pharmaceutical Industries from an ‘equal weight’ rating to an ‘overweight’ rating and raised its price target for the stock from $11.00 to $13.00 in a report research on Tuesday, April 5. Argus downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a Thursday, Jan. 27 research note. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a Tuesday, April 5 research note. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries from a “sell” rating to a “hold” rating and set a price target of $11.00 for the company in a Tuesday, April 12 research note. Finally, Sanford C. Bernstein upgraded shares of Teva Pharmaceutical Industries from a “market performance” rating to an “outperform” rating and set a price target of $11.00 for the company in a rating note. research from Friday, March 25. Five investment analysts gave the stock a hold rating and three gave the stock a buy rating. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $11.83.
In other Teva Pharmaceutical Industries news, Executive Vice President Eli Shani sold 5,311 shares of the company in a trade on Monday, February 28. The shares were sold at an average price of $8.14, for a total value of $43,231.54. The sale was disclosed in a filing with the Securities & Exchange Commission, available via this hyperlink. Also, Vice President David Matthew Stark sold 6,110 shares of Teva Pharmaceutical Industries in a trade on Wednesday, February 9. The stock was sold at an average price of $9.06, for a total transaction of $55,356.60. Disclosure of this sale can be found here. Insiders sold a total of 22,011 shares of the company valued at $188,598 during the last quarter. 0.74% of the shares are held by insiders of the company.
A number of institutional investors have recently bought and sold shares of TEVA. Fieldpoint Private Securities LLC increased its stake in Teva Pharmaceutical Industries by 100,000.0% in the first quarter. Fieldpoint Private Securities LLC now owns 3,003 shares of the company worth $28,000 after purchasing an additional 3,000 shares in the last quarter. Koshinski Asset Management Inc. increased its stake in Teva Pharmaceutical Industries by 61.6% in the fourth quarter. Koshinski Asset Management Inc. now owns 3,934 shares of the company worth $32,000 after purchasing an additional 1,500 shares in the last quarter. Kistler Tiffany Companies LLC increased its stake in Teva Pharmaceutical Industries by 932.2% in the fourth quarter. Kistler Tiffany Companies LLC now owns 4,139 shares of the company worth $33,000 after purchasing 3,738 additional shares in the last quarter. Huntington National Bank increased its stake in Teva Pharmaceutical Industries by 115.7% in the fourth quarter. Huntington National Bank now owns 4,850 shares of the company worth $38,000 after buying 2,601 additional shares in the last quarter. Finally, Future Financial Wealth Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter, valued at around $49,000. 47.60% of the shares are held by institutional investors and hedge funds.
Shares of NYSE: TEVA traded at $0.01 during Monday’s trading, reaching $9.13. 7,025,542 shares of the company were traded, against an average volume of 8,719,978. The company has a market capitalization of $10.07 billion, a P/E ratio of 24.03, a price/growth ratio of earnings of 1.05 and a beta of 1.22. Teva Pharmaceutical Industries has a 1-year low of $7.24 and a 1-year high of $11.55. The company’s 50-day moving average is $8.67 and its 200-day moving average is $8.79. The company has a quick ratio of 0.79, a current ratio of 1.14 and a debt ratio of 1.92.
Teva Pharmaceutical Industries Company Profile (Get a rating)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generic drugs, specialty drugs and biopharmaceuticals in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams.
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
Get news and reviews for Teva Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily newsletter.